Skip to main content

Advertisement

SpringerLink
Log in

Adjuvant and chemopreventive therapies for resectable hepatocellular carcinoma: a literature review

  • Review
  • Published:
Tumor Biology

Abstract

The recurrence rate of hepatocellular carcinoma (HCC) after potentially curative hepatic resection (HR) is very high. Many clinical trials have explored the efficacy of several treatment modalities to prevent recurrence, including adjuvant and chemopreventive therapy, but they have often reported contradictory findings. As a result, most liver guidelines and liver seminars do not unequivocally endorse adjuvant or chemopreventive therapy for HCC patients after potentially curative HR. To examine the available evidence on this question, we comprehensively searched PubMed for controlled studies that included a supportive care or placebo control arm, and we used the GRADE system to classify and assess the results.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30.

    Article  PubMed  Google Scholar 

  2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.

    Article  PubMed  Google Scholar 

  3. Zhang CY, Huang TR, Yu JH, et al. Epidemiological analysis of primary liver cancer in the early 21st century in Guangxi province of China. Chin J Cancer. 2010;29(5):545–50.

    Article  PubMed  Google Scholar 

  4. Hatzaras I, Bischof DA, Fahy B, Cosgrove D, Pawlik TM. Treatment options and surveillance strategies after therapy for hepatocellular carcinoma. Ann Surg Oncol. 2014;21(3):758–66.

    Article  PubMed  Google Scholar 

  5. Lok AS, Seeff LB, Morgan TR, et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology. 2009;136(1):138–48.

    Article  CAS  PubMed  Google Scholar 

  6. Naito S, Imamura H, Tukada A, et al. Postoperative recurrence pattern and prognosis of patients with hepatocellular carcinoma, with particular reference to the hepatitis viral infection status. Liver Int. 2014;34(5):802–13.

    Article  PubMed  Google Scholar 

  7. Zhong JH, Ke Y, Gong WF, et al. Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma. Ann Surg. 2014;260(2):329–40.

    Article  PubMed  Google Scholar 

  8. Zhong JH, Xiang BD, Gong WF, et al. Comparison of long-term survival of patients with BCLC stage B hepatocellular carcinoma after liver resection or transarterial chemoembolization. PLoS ONE. 2013;8(7):e68193.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Ke Y, Zhong JH, Guo Z, Liang YR, Li LQ, Xiang BD. Comparison liver resection with transarterial chemoembolization for Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma patients on long-term survival after SPSS propensity score matching. Natl Med J China. 2014;94(10):747–50.

    CAS  Google Scholar 

  10. Lim KC, Chow PK, Allen JC, Siddiqui FJ, Chan ES, Tan SB. Systematic review of outcomes of liver resection for early hepatocellular carcinoma within the Milan criteria. Br J Surg. 2012;99(12):1622–9.

    Article  PubMed  Google Scholar 

  11. Oxford Centre for Evidence-based Medicine—Levels of Evidence (March 2009) [DB/OL]. Oxford Centre for Evidence-based Medicine, 2009 [2014-7-28].http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/.

  12. Schünemann HJ, Oxman AD, Brozek J, et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ. 2008;336(7653):1106–10.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Zhong JH, Li H, Li LQ, et al. Adjuvant therapy options following curative treatment of hepatocellular carcinoma: a systematic review of randomized trials. Eur J Surg Oncol. 2012;38(4):286–95.

    Article  PubMed  Google Scholar 

  14. Choi KK, Kim SH, Choi SB, et al. Portal venous invasion: the single most independent risk factor for immediate postoperative recurrence of hepatocellular carcinoma. J Gastroenterol Hepatol. 2011;26(11):1646–51.

    Article  PubMed  Google Scholar 

  15. Huang L, Li J, Yan J, et al. Early recurrence after curative resection in oligonodular hepatocellular carcinoma. HepatoGastroenterology. 2013;60(121):28–31.

    PubMed  Google Scholar 

  16. Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38(2):200–7.

    Article  PubMed  Google Scholar 

  17. Kubo S, Yamamoto T, Ikebe T, et al. Relationship between multicentric occurrence of hepatocellular carcinoma and histology of noncancerous hepatic tissue in patients with chronic hepatitis C. Jpn J Cancer Res. 1999;90(10):1076–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Li SH, Guo ZX, Xiao CZ, et al. Risk factors for early and late intrahepatic recurrence in patients with single hepatocellular carcinoma without macrovascular invasion after curative resection. Asian Pac J Cancer Prev. 2013;14(8):4759–63.

    Article  PubMed  Google Scholar 

  19. Kim BK, Park JY, Kim do Y, et al. Persistent hepatitis B viral replication affects recurrence of hepatocellular carcinoma after curative resection. Liver Int. 2008;28(3):393–401.

    Article  CAS  PubMed  Google Scholar 

  20. Hung IF, Poon RT, Lai CL, Fung J, Fan ST, Yuen MF. Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection. Am J Gastroenterol. 2008;103(7):1663–73.

    Article  PubMed  Google Scholar 

  21. Chuma M, Hige S, Kamiyama T, et al. The influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma. J Gastroenterol. 2009;44(9):991–9.

    Article  CAS  PubMed  Google Scholar 

  22. Yamashita Y, Shirabe K, Toshima T, et al. Risk factors for recurrence after curative resection of hepatitis C-related hepatocellular carcinoma in patients without postoperative interferon therapy. Hepatol Res. 2013;43(12):1313–20.

    Article  CAS  PubMed  Google Scholar 

  23. Hanazaki K, Wakabayashi M, Sodeyama H, Kajikawa S, Amano J. Hepatic function immediately after hepatectomy as a significant risk factor for early recurrence in hepatocellular carcinoma. HepatoGastroenterology. 1999;46(30):3201–7.

    CAS  PubMed  Google Scholar 

  24. Tangkijvanich P, Anukulkarnkusol N, Suwangool P, et al. Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. J Clin Gastroenterol. 2000;31(4):302–8.

    Article  CAS  PubMed  Google Scholar 

  25. Ladhams A, Schmidt C, Sing G, et al. Treatment of non-resectable hepatocellular carcinoma with autologous tumor-pulsed dendritic cells. J Gastroenterol Hepatol. 2002;17(8):889–96.

    Article  PubMed  Google Scholar 

  26. Ohira M, Ohdan H, Mitsuta H, et al. Adoptive transfer of TRAIL-expressing natural killer cells prevents recurrence of hepatocellular carcinoma after partial hepatectomy. Transplantation. 2006;82(12):1712–9.

    Article  CAS  PubMed  Google Scholar 

  27. Kaibori M, Ishizaki M, Matsui K, Kwon AH. Predictors of microvascular invasion before hepatectomy for hepatocellular carcinoma. J Surg Oncol. 2010;102(5):462–8.

    Article  CAS  PubMed  Google Scholar 

  28. Funaki NO, Tanaka J, Seto SI, Kasamatsu T, Kaido T, Imamura M. Hematogenous spreading of hepatocellular carcinoma cells: possible participation in recurrence in the liver. Hepatology. 1997;25(3):564–8.

    Article  CAS  PubMed  Google Scholar 

  29. Zhong JH, Ma L, Li LQ. Postoperative therapy options for hepatocellular carcinoma. Scand J Gastroenterol. 2014;49(6):649–61.

    Article  CAS  PubMed  Google Scholar 

  30. Izumi R, Shimizu K, Iyobe T, et al. Postoperative adjuvant hepatic arterial infusion of Lipiodol containing anticancer drugs in patients with hepatocellular carcinoma. Hepatology. 1994;20(2):295–301.

    Article  CAS  PubMed  Google Scholar 

  31. Zhong JH, Li LQ. Postoperative adjuvant transarterial chemoembolization for participants with hepatocellular carcinoma: a meta-analysis. Hepatol Res. 2010;40(10):943–53.

    Article  CAS  PubMed  Google Scholar 

  32. Xi T, Lai EC, Min AR, et al. Adjuvant transarterial chemoembolization after curative resection of hepatocellular carcinoma: a non-randomized comparative study. HepatoGastroenterology. 2012;59(116):1198–203.

    PubMed  Google Scholar 

  33. Chen X, Zhang B, Yin X, Ren Z, Qiu S, Zhou J. Lipiodolized transarterial chemoembolization in hepatocellular carcinoma patients after curative resection. J Cancer Res Clin Oncol. 2013;139(5):773–81.

    Article  CAS  PubMed  Google Scholar 

  34. Kim do Y, Ahn SH, Kim SU, et al. Adjuvant hepatic arterial infusional chemotherapy with 5-fluorouracil and cisplatin after curative resection of hepatocellular carcinoma. Oncology. 2011;81(3–4):184–91.

    Article  PubMed  CAS  Google Scholar 

  35. Ono T, Nagasue N, Kohno H, et al. Adjuvant chemotherapy with epirubicin and carmofur after radical resection of hepatocellular carcinoma: a prospective randomized study. Semin Oncol. 1997;24(2 Suppl 6):S6-18–16-25.

    Google Scholar 

  36. Ono T, Yamanoi A, Nazmy El Assal O, Kohno H, Nagasue N. Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients: metaanalysis of three randomized controlled trials. Cancer. 2001;91(12):2378–85.

    Article  CAS  PubMed  Google Scholar 

  37. Lai EC, Lo CM, Fan ST, Liu CL, Wong J. Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma: a randomized controlled trial. Arch Surg. 1998;133(2):183–8.

    Article  CAS  PubMed  Google Scholar 

  38. Meyer T, Kirkwood A, Roughton M, et al. A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma. Br J Cancer. 2013;108(6):1252–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Tsochatzis EA, Fatourou E, O’Beirne J, Meyer T, Burroughs AK. Transarterial chemoembolization and bland embolization for hepatocellular carcinoma. World J Gastroenterol. 2014;20(12):3069–77.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Lau WY, Leung TW, Ho SK, et al. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet. 1999;353(9155):797–801.

    Article  CAS  PubMed  Google Scholar 

  41. Chung AY, Ooi LL, Machin D, et al. Adjuvant hepatic intra-arterial iodine-131-lipiodol following curative resection of hepatocellular carcinoma: a prospective randomized trial. World J Surg. 2013;37(6):1356–61.

    Article  CAS  PubMed  Google Scholar 

  42. Dumortier J, Decullier E, Hilleret MN, et al. Adjuvant intraarterial lipiodol or 131I-lipiodol after curative treatment of hepatocellular carcinoma: a prospective randomized trial. J Nucl Med. 2014;55(6):877–83.

    Article  CAS  PubMed  Google Scholar 

  43. Boucher E, Corbinais S, Rolland Y, et al. Adjuvant intra-arterial injection of iodine-131-labeled lipiodol after resection of hepatocellular carcinoma. Hepatology. 2003;38(5):1237–41.

    Article  CAS  PubMed  Google Scholar 

  44. Boucher E, Bouguen G, Garin E, Guillygomarch A, Boudjema K, Raoul JL. Adjuvant intraarterial injection of 131I-labeled lipiodol after resection of hepatocellular carcinoma: progress report of a case-control study with a 5-year minimal follow-up. J Nucl Med. 2008;49(3):362–6.

    Article  PubMed  Google Scholar 

  45. Chua TC, Saxena A, Chu F, et al. Hepatic resection with or without adjuvant iodine-131-lipiodol for hepatocellular carcinoma: a comparative analysis. Int J Clin Oncol. 2011;16(2):125–32.

    Article  CAS  PubMed  Google Scholar 

  46. Tabone M, Vigano L, Ferrero A, Pellerito R, Carbonatto P, Capussotti L. Prevention of intrahepatic recurrence by adjuvant (131)iodine-labeled lipiodol after resection for hepatocellular carcinoma in HCV-related cirrhosis. Eur J Surg Oncol. 2007;33(1):61–6.

    Article  CAS  PubMed  Google Scholar 

  47. Gong L, Shi L, Sun J, et al. Comparative survival analysis of adjuvant therapy with iodine-131-labeled lipiodol to hepatic resection of primary hepatocellular carcinoma: a meta-analysis. Nucl Med Commun. 2014;35(5):484–92.

    Article  CAS  PubMed  Google Scholar 

  48. Ma L, Zhong JH, Li LQ, et al. Postoperative transarterial chemoembolization on patients with hepatocellular carcinoma: a systematic review. Chin J Oncol Prev Treat. 2011;3(1):74–81.

    Google Scholar 

  49. Yamamoto M, Arii S, Sugahara K, Tobe T. Adjuvant oral chemotherapy to prevent recurrence after curative resection for hepatocellular carcinoma. Br J Surg. 1996;83(3):336–40.

    Article  CAS  PubMed  Google Scholar 

  50. Hasegawa K, Takayama T, Ijichi M, et al. Uracil-tegafur as an adjuvant for hepatocellular carcinoma: a randomized trial. Hepatology. 2006;44(4):891–5.

    Article  CAS  PubMed  Google Scholar 

  51. Xia Y, Qiu Y, Li J, et al. Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: a randomized controlled trial. Ann Surg Oncol. 2010;17(12):3137–44.

    Article  PubMed  Google Scholar 

  52. Zhong JH, Li LQ. Conventional oral systemic chemotherapy for postoperative hepatocellular carcinoma. J Canc Res Updat. 2014;3(1):11–8.

    CAS  Google Scholar 

  53. Qin C, Zhong JH, Li LQ, et al. Postoperative adjuvant oral chemotherapy for hepatocellular carcinoma: a meta-analysis. Chin J Oncol Prev Treat. 2012;4(1):65–70.

    Google Scholar 

  54. Chen K, Xia Y, Wang H, Xiao F, Xiang G, Shen F. Adjuvant iodine-125 brachytherapy for hepatocellular carcinoma after complete hepatectomy: a randomized controlled trial. PLoS ONE. 2013;8(2):e57397.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Kulik LM, Carr BI, Mulcahy MF, et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology. 2008;47(1):71–81.

    Article  PubMed  Google Scholar 

  56. Young JY, Rhee TK, Atassi B, et al. Radiation dose limits and liver toxicities resulting from multiple yttrium-90 radioembolization treatments for hepatocellular carcinoma. J Vasc Interv Radiol. 2007;18(11):1375–82.

    Article  PubMed  Google Scholar 

  57. Ikeda K, Arase Y, Saitoh S, et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor—a prospective randomized study of hepatitis C virus-related liver cancer. Hepatology. 2000;32(2):228–32.

    Article  CAS  PubMed  Google Scholar 

  58. Chen LT, Chen MF, Li LA, et al. Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection. Ann Surg. 2012;255(1):8–17.

    Article  PubMed  Google Scholar 

  59. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Kinoshita H. Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg. 2002;89(4):418–22.

    Article  CAS  PubMed  Google Scholar 

  60. Lin SM, Lin CJ, Hsu CW, et al. Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer. 2004;100(2):376–82.

    Article  CAS  PubMed  Google Scholar 

  61. Lo CM, Liu CL, Chan SC, et al. A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg. 2007;245(6):831–42.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Mazzaferro V, Romito R, Schiavo M, et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology. 2006;44(6):1543–54.

    Article  CAS  PubMed  Google Scholar 

  63. Shiratori Y, Shiina S, Teratani T, et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med. 2003;138(4):299–306.

    Article  PubMed  Google Scholar 

  64. Sun HC, Tang ZY, Wang L, et al. Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol. 2006;132(7):458–65.

    Article  CAS  PubMed  Google Scholar 

  65. Singal AK, Freeman Jr DH, Anand BS. Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma. Aliment Pharmacol Ther. 2010;32(7):851–8.

    Article  CAS  PubMed  Google Scholar 

  66. Huang TS, Shyu YC, Chen HY, Yuan SS, Shih JN, Chen PJ. A systematic review and meta-analysis of adjuvant interferon therapy after curative treatment for patients with viral hepatitis-related hepatocellular carcinoma. J Viral Hepat. 2013;20(10):729–43.

    Article  PubMed  Google Scholar 

  67. Miao RY, Zhao HT, Yang HY, et al. Postoperative adjuvant antiviral therapy for hepatitis B/C virus-related hepatocellular carcinoma: a meta-analysis. World J Gastroenterol. 2010;16(23):2931–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Xu JB, Qi FZ, Xu G, Chen GF, Huang MD, Zhang JH. Adjuvant interferon therapy after surgical treatment for hepatitis B/C virus-related hepatocellular carcinoma: a meta-analysis. Hepatol Res. 2014;44(2):209–17.

    Article  CAS  PubMed  Google Scholar 

  69. Zhang CH, Xu GL, Jia WD, Li JS, Ma JL, Ge YS. Effects of interferon treatment on development and progression of hepatocellular carcinoma in patients with chronic virus infection: a meta-analysis of randomized controlled trials. Int J Cancer. 2011;129(5):1254–64.

    Article  CAS  PubMed  Google Scholar 

  70. Ormeci N. Short- and long-term effects of treatment of chronic hepatitis B and delta virus by IFN. Fundam Clin Pharmacol. 2003;17(6):651–8.

    Article  PubMed  Google Scholar 

  71. Yamazhan T, Kurtaran B, Pullukcu H, et al. Pegylated interferon in HBeAg-positive and -negative chronic hepatitis B patients: post-treatment 1-year results of three Turkish centres. J Chemother. 2013;1973947813Y0000000152.

  72. Murata M, Nabeshima S, Kikuchi K, Yamaji K, Furusyo N, Hayashi J. A comparison of the antitumor effects of interferon-alpha and beta on human hepatocellular carcinoma cell lines. Cytokine. 2006;33(3):121–8.

    Article  CAS  PubMed  Google Scholar 

  73. Damdinsuren B, Nagano H, Wada H, et al. Stronger growth-inhibitory effect of interferon (IFN)-beta compared to IFN-alpha is mediated by IFN signaling pathway in hepatocellular carcinoma cells. Int J Oncol. 2007;30(1):201–8.

    CAS  PubMed  Google Scholar 

  74. Yamaji K, Nabeshima S, Murata M, et al. Interferon-alpha/beta upregulate IL-15 expression in vitro and in vivo: analysis in human hepatocellular carcinoma cell lines and in chronic hepatitis C patients during interferon-alpha/beta treatment. Cancer Immunol Immunother. 2006;55(4):394–403.

    Article  CAS  PubMed  Google Scholar 

  75. Kubo S, Hirohashi K, Tanaka H, et al. Effect of viral status on recurrence after liver resection for patients with hepatitis B virus-related hepatocellular carcinoma. Cancer. 2000;88(5):1016–24.

    Article  CAS  PubMed  Google Scholar 

  76. Wu JC, Huang YH, Chau GY, et al. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol. 2009;51(5):890–7.

    Article  PubMed  Google Scholar 

  77. Singal AK, Salameh H, Kuo YF, Fontana RJ. Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B. Aliment Pharmacol Ther. 2013;38(2):98–106.

    Article  CAS  PubMed  Google Scholar 

  78. Ke Y, Ma L, You XM, et al. Antiviral therapy for hepatitis B virus-related hepatocellular carcinoma after radical hepatectomy. Cancer Biol Med. 2013;10(3):158–64.

    PubMed  PubMed Central  Google Scholar 

  79. Wu CY, Chen YJ, Ho HJ, et al. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA. 2012;308(18):1906–14.

    Article  CAS  PubMed  Google Scholar 

  80. Wong JS, Wong GL, Tsoi KK, et al. Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Ther. 2011;33(10):1104–12.

    Article  PubMed  Google Scholar 

  81. Yin J, Li N, Han Y, et al. Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study. J Clin Oncol. 2013;31(29):3647–55.

    Article  CAS  PubMed  Google Scholar 

  82. Zhong JH, Li le Q, Wu LC. Lamivudine with or without adefovir dipivoxil for postoperative hepatocellular carcinoma. Cochrane Database Syst Rev. 2011;(12):CD008713.

  83. Huang L, Li J, Lau WY, et al. Perioperative reactivation of hepatitis B virus replication in patients undergoing partial hepatectomy for hepatocellular carcinoma. J Gastroenterol Hepatol. 2012;27(1):158–64.

    Article  CAS  PubMed  Google Scholar 

  84. Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 2002;347(3):168–74.

    Article  CAS  PubMed  Google Scholar 

  85. Chan HL, Tse CH, Mo F, et al. High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol. 2008;26(2):177–82.

    Article  CAS  PubMed  Google Scholar 

  86. Cheung YS, Chan HL, Wong J, et al. Elevated perioperative transaminase level predicts intrahepatic recurrence in hepatitis B-related hepatocellular carcinoma after curative hepatectomy. Asian J Surg. 2008;31(2):41–9.

    Article  PubMed  Google Scholar 

  87. Huang Y, Wang Z, An S, et al. Role of hepatitis B virus genotypes and quantitative HBV DNA in metastasis and recurrence of hepatocellular carcinoma. J Med Virol. 2008;80(4):591–7.

    Article  CAS  PubMed  Google Scholar 

  88. Chan AC, Chok KS, Yuen WK, et al. Impact of antiviral therapy on the survival of patients after major hepatectomy for hepatitis B virus-related hepatocellular carcinoma. Arch Surg. 2011;146(6):675–81.

    Article  PubMed  Google Scholar 

  89. Zhong JH, Mo XS, Xiang BD, et al. Postoperative use of the chemopreventive vitamin K2 analog in patients with hepatocellular carcinoma. PLoS ONE. 2013;8(3):e58082.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Zhong JH, Gong WF, Li LQ, et al. Meta-analysis of postoperative chemopreventive vitamin K2 analog for patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 2012;27 Suppl 5:212–3.

    Google Scholar 

  91. Yoshida H, Shiratori Y, Kudo M, et al. Effect of vitamin K2 on the recurrence of hepatocellular carcinoma. Hepatology. 2011;54(2):532–40.

    Article  CAS  PubMed  Google Scholar 

  92. Muto Y, Moriwaki H, Ninomiya M, et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med. 1996;334(24):1561–7.

    Article  CAS  PubMed  Google Scholar 

  93. Liu CJ, Lee PH, Lin DY, et al. Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage. J Hepatol. 2009;50(5):958–68.

    Article  CAS  PubMed  Google Scholar 

  94. Wang SN, Chuang SC, Lee KT. Efficacy of sorafenib as adjuvant therapy to prevent early recurrence of hepatocellular carcinoma after curative surgery: a pilot study. Hepatol Res. 2014;44(5):523–31.

    Article  CAS  PubMed  Google Scholar 

  95. Zhong JH, Ma L, Li LQ, Ru HM, Zhao YN. Adjuvant imatinib for gastrointestinal stromal tumors: the current situation and problems. Scand J Gastroenterol. 2011;46(6):645–51.

    Article  CAS  PubMed  Google Scholar 

  96. Takayama T, Sekine T, Makuuchi M, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet. 2000;356(9232):802–7.

    Article  CAS  PubMed  Google Scholar 

  97. Hui D, Qiang L, Jian W, Ti Z, Da-Lu K. A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma. Dig Liver Dis. 2009;41(1):36–41.

    Article  PubMed  CAS  Google Scholar 

  98. Weng DS, Zhou J, Zhou QM, et al. Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas. J Immunother. 2008;31(1):63–71.

    Article  PubMed  Google Scholar 

  99. Zhong JH, Ma L, Wu LC, et al. Adoptive immunotherapy for postoperative hepatocellular carcinoma: a systematic review. Int J Clin Pract. 2012;66(1):21–7.

    Article  PubMed  Google Scholar 

  100. Kuang M, Peng BG, Lu MD, et al. Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma. Clin Cancer Res. 2004;10(5):1574–9.

    Article  CAS  PubMed  Google Scholar 

  101. Guo Z, Zhong JH, Jiang JH, Zhang J, Xiang BD, Li LQ. Comparison of survival of patients with BCLC stage A hepatocellular carcinoma after hepatic resection or transarterial chemoembolization: a propensity score-based analysis. Ann Surg Oncol. 2014;21(9):3069–76.

  102. Ishihara T, Iwasa M, Tanaka H, et al. Effect of branched-chain amino acids in patients receiving intervention for hepatocellular carcinoma. World J Gastroenterol. 2014;20(10):2673–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Kakazu E, Kondo Y, Kogure T, et al. Supplementation of branched-chain amino acids maintains the serum albumin level in the course of hepatocellular carcinoma recurrence. Tohoku J Exp Med. 2013;230(4):191–6.

    Article  CAS  PubMed  Google Scholar 

  104. Meng J, Zhong J, Zhang H, et al. Pre-, peri-, and postoperative oral administration of branched-chain amino acids for primary liver cancer patients for hepatic resection: a systematic review. Nutr Cancer. 2014;66(3):517–22.

    Article  CAS  PubMed  Google Scholar 

  105. Meng WC, Leung KL, Ho RL, Leung TW, Lau WY. Prospective randomized control study on the effect of branched-chain amino acids in patients with liver resection for hepatocellular carcinoma. Aust N Z J Surg. 1999;69(11):811–5.

    Article  CAS  PubMed  Google Scholar 

  106. Long-term oral administration of branched chain amino acids after curative resection of hepatocellular carcinoma: a prospective randomized trial. The San-in Group of Liver Surgery. Br J Surg. 1997;84(11):1525–31.

  107. Okabayashi T, Iyoki M, Sugimoto T, Kobayashi M, Hanazaki K. Oral supplementation with carbohydrate- and branched-chain amino acid-enriched nutrients improves postoperative quality of life in patients undergoing hepatic resection. Amino Acids. 2011;40(4):1213–20.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by the Self-raised Scientific Research Fund of the Ministry of Health of Guangxi Province (nos. Z2012345 and Z2014241) and the Youth Science Foundation of Guangxi Medical University (no. GXMUYSF201302).

Author information

Authors and Affiliations

  1. Department of Hepatobiliary Surgery, Affiliated Tumor Hospital of Guangxi Medical University, He Di Rd. #71, Nanning, 530021, People’s Republic of China

    Jian-Hong Zhong & Le-Qun Li

  2. Second Department of Radiotherapy, Wuzhou Red Cross Hospital, Wuzhou, 543002, People’s Republic of China

    Qing-Lian Zhong

  3. Department of Ultrasound, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, 530021, People’s Republic of China

    Hang Li

Authors
  1. Jian-Hong Zhong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Qing-Lian Zhong
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Le-Qun Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hang Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Le-Qun Li or Hang Li.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhong, JH., Zhong, QL., Li, LQ. et al. Adjuvant and chemopreventive therapies for resectable hepatocellular carcinoma: a literature review. Tumor Biol. 35, 9459–9468 (2014). https://doi.org/10.1007/s13277-014-2443-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-2443-6

Keywords

Search

Navigation